Reference standard comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid, may form a loose cake |
| Solubility class | Soluble in water | Practically insoluble in nonpolar solvents |
| Storage temperature, solid | -20 °C or below | Desiccated and protected from light |
| Storage temperature, liquid | 2-8 °C | Refrigerated, not frozen |
| Typical identity method | LC-MS | Observed mass compared with calculated mass |
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
=== Frozen fish food === Perishable food can be preserved by frozen storage, and is often sold in blister packs or resealable packets. These can contain a variety of ingredients such as bloodworms, Daphnia, or brine shrimp, and are commonly used to feed such fish as Discus which require a high protein diet. Often fed on beef heart fish food within the aquaculture industry, the discus fish are not the only fish which can benefit from a high quality prepared frozen mixture such as beef heart, although by far these are the fish most associated with this particular frozen food.
The majority of tulip cultivars are classified in the taxon Tulipa gesneriana. They have usually several species in their direct background, but most have been derived from Tulipa suaveolens. Tulipa gesneriana is in itself an early hybrid of complex origin and is probably not the same taxon as was described by Conrad Gessner in the 16th century. The UK's National Collection of English florists' tulips and Dutch historic tulips, dating from the early 17th century to c. 1960, is held by Polly Nicholson at Blackland House, near Calne in Wiltshire.
When the Basilica of Saint-Denis was desecrated by French revolutionaries in 1793, the body of Henry IV was so well preserved it was displayed two days before being thrown in a mass grave, and a new death mask was able to be made. Likewise, Louis XIII was still recognisable thanks to his well preserved moustache. Turenne was so well preserved that looters first thought he was still alive. Maria II of Portugal died in childbirth on 15 November 1853, at the age of 34. Her embalming was conducted the following day and proved to be a complex procedure due to the rapid post-mortem changes in her remains. The Duchess of Ficalho, the queen's lady-in-waiting, provided a primary account of the event in a letter to her brother, the 2nd Count of Lavradio: The sad embalming took place on November 16th, and I was present throughout. The procedure for the Infante and the Queen lasted seven hours. Once that ordeal was over, it was time to dress the body, which was nearly impossible due to the state of dissolution of Her Majesty. Nevertheless, it was done as well as possible, including the placement of the Orders and the Royal Mantle. It was ultimately necessary to close the coffin, for the state of dissolution was beyond description. In 2012, an exhumation of the remains of Amélie of Leuchtenberg (1812–1873), Empress of Brazil, revealed that her body had undergone extensive long-term preservation. Despite being interred for 139 years, the body was found mummified with skin, hair, and internal organs intact.
=== Laboratory synthesis === Formaldehyde was discovered in 1859 by the Russian chemist Aleksandr Butlerov (1828–1886) when he tried to synthesize methanediol ("methylene glycol") from iodomethane and silver oxalate. In his paper, Butlerov called formaldehyde "dioxymethylen" (methylene dioxide) because his empirical formula for it was incorrect, as atomic weights were not precisely determined until the Karlsruhe Congress. August Wilhelm von Hofmann first identified the compound as an aldehyde. He announced its production by passing methanol vapor in air over hot platinum wire. With modifications, Hofmann's method remains the basis of the modern industrial route. Solution routes to formaldehyde also entail oxidation of methanol or iodomethane.
==== Gastrointestinal and colorectal cancer ==== Reviews of preliminary clinical trials on people with colorectal or gastrointestinal cancer suggest that soy isoflavones may have a slight protective effect against such cancers.
Sources: en.wikipedia.org
atomic number (Z) Also proton number. The number of protons found in the nucleus of an atom of a given chemical element. It is identical to the charge number of the nucleus and is used in the periodic table to uniquely identify each chemical element.
== Structure and classification == Aminopeptidases are a diverse group of enzymes that play crucial roles in various biological processes, including protein digestion, cell growth, and immune response. They are classified based on their substrate specificity (strength of binding) and catalytic mechanism (means of catalyzing their reaction) into two main categories: metalloaminopeptidases and cysteine aminopeptidases. Metalloaminopeptidases use a metal ion to perform their function, and cysteine aminopeptidases use a particular cysteine amino acid. The structure of aminopeptidases varies depending on the specific enzyme, but they generally consist of a catalytic domain where the catalysis occurs and additional domains that contribute to target recognition and regulation of their functions. For instance, Aminopeptidase N (APN), a type II metalloprotease, consists of 967 amino acids with a short N-terminal cytoplasmic domain in the cytoplasm, a single transmembrane part reaching through the cellular membrane, and a large cellular ectodomain sticking out of the cell containing the active site.
Recent theoretical developments in noble gas chemistry, in which helium is expected to show slightly less inertness than neon and to form (HeO)(LiF)2 with a structure similar to the analogous beryllium compound (but with no expected neon analogue), have resulted in more chemists advocating a placement of helium in group 2. This relates to the electronic argument, as the reason for neon's greater inertness is repulsion from its filled p-shell that helium lacks, though realistically it is unlikely that helium-containing molecules will be stable outside extreme low-temperature conditions (around 10 K). The first-row anomaly in the periodic table has additionally been cited to support moving helium to group 2. It arises because the first orbital of any type is unusually small, since unlike its higher analogues, it does not experience interelectronic repulsion from a smaller orbital of the same type. This makes the first row of elements in each block have unusually small atoms, and such elements tend to exhibit characteristic kinds of anomalies for their group. Some chemists arguing for the repositioning of helium have pointed out that helium exhibits similar anomalies if it is placed in group 2, but not if it is placed in group 18: on the other hand, neon, which would be the first group 18 element if helium was removed from that spot, does exhibit similar anomalies. The relationship between helium and beryllium is then argued to resemble that between hydrogen and lithium, a placement which is much more commonly accepted.
== Stigma == A 2016 report on stigma concluded "there is no country, society or culture where people with mental illness have the same societal value as people without mental illness". It is also important to comprehend that there are different types of stigmas: the most commonly understood is public stigma, which involves the negative or discriminatory attitudes that others may have about mental illness; it often leads to a more structural stigma, which involves policies of government and private organizations that intentionally or unintentionally limit opportunities for people with mental illness (examples include lower budgets for mental illness research or fewer mental health services in comparison to other types health care); finally, it is unavoidable to not talk about self-stigma, which refers to the negative attitudes, including internalized shame, that people with mental illness may have about their own condition. And stigma about mental illnesses seems to be widely endorsed as well as many misconceptions, the more common being: people with mental illness are homicidal maniacs who need to be feared; they have childlike perceptions of the world that should be marveled; or they are responsible for their illness because they have weak character. Indeed, the public seems to disapprove of people with psychiatric disabilities significantly more than people with related conditions such as physical illness. Severe mental illness has been likened to drug addiction, prostitution, and criminality.
== Clinical Evidence & Applications == Clinical and research studies suggest ZnC supports intestinal barrier function and may reduce inflammation in conditions like ulcerative colitis. Human and animal studies demonstrate mucosal protection against chemical injury and improved reparative responses. Reviews of clinical studies show benefit in oral and esophageal mucositis in cancer patients receiving chemoradiation, attributed to epithelial protection. Evidence supports the safety and efficacy of ZnC for the maintenance, prevention, and treatment of the mucosal lining and other epithelial tissues. The research supports its use for gastric ulcers and conditions of the upper GI and suggests other applications, particularly for oral mucositis.
Sources: en.wikipedia.org
== Reaction mechanism == BHBDH is found in the mitochondria and catalyzes the oxidation of 3-hydroxybutyyrate to acetoacetate and it uses NAD as a coenzyme. The reaction is shown below and as denoted by the formula it is reversible. As outlined in the reaction formula, this enzyme catalyzes the reaction of (R)-3-hydroxybutanoate and NAD+ into acetoacetate into NADH and a free H+. (R)-3-hydroxybutanoate + NAD+
== Structure == SUMO proteins are small; most are around 100 amino acids in length and 12 kDa in mass. The exact length and mass varies between SUMO family members and depends on which organism the protein comes from. Although SUMO has very little sequence identity with ubiquitin (less than 20%) at the amino acid level, it has a nearly identical structural fold. SUMO protein has a unique N-terminal extension of 10-25 amino acids which other ubiquitin-like proteins do not have. This N-terminal is found related to the formation of SUMO chains. The structure of human SUMO1 is depicted on the right. It shows SUMO1 as a globular protein with both ends of the amino acid chain (shown in red and blue) sticking out of the protein's centre. The spherical core consists of an alpha helix and a beta sheet. The diagrams shown are based on an NMR analysis of the protein in solution.
The first observations and size measurements of nano-particles were made during the first decade of the 20th century. Zsigmondy made detailed studies of gold sols and other nanomaterials with sizes down to 10 nm and less. He published a book in 1914. He used an ultramicroscope that employs a dark field method for seeing particles with sizes much less than light wavelength. There are traditional techniques developed during the 20th century in interface and colloid science for characterizing nanomaterials. These are widely used for first generation passive nanomaterials specified in the next section. These methods include several different techniques for characterizing particle size distribution. This characterization is imperative because many materials that are expected to be nano-sized are actually aggregated in solutions. Some of methods are based on light scattering. Others apply ultrasound, such as ultrasound attenuation spectroscopy for testing concentrated nano-dispersions and microemulsions. There is also a group of traditional techniques for characterizing surface charge or zeta potential of nano-particles in solutions. This information is required for proper system stabilization, preventing its aggregation or flocculation. These methods include microelectrophoresis, electrophoretic light scattering, and electroacoustics. The last one, for instance colloid vibration current method is suitable for characterizing concentrated systems.
=== Kl--Ku === Martin Heinrich Klaproth (1743–1817), German chemist, who discovered uranium and zirconium, and contributed to the discovery of other elements Trevor Kletz (1922–2013), British promoter of industrial safety Aaron Klug (1926–2018), winner of the 1982 Nobel Prize in Chemistry for developing crystallographic electron microscopy Emil Knoevenagel (1865–1921) German organic chemist, known for the condensation reaction of carbonyl compounds with active methylene compounds Jeremy Randall Knowles (1935–2008), British physical organic chemist known for studies of chemical mechanisms, especially in enzyme catalysis William Standish Knowles (1917–2012), 2001 Nobel Prize in Chemistry for work on asymmetric synthesis, specifically in hydrogenation reactions Walter Kohn (1923–2016), 1998 Nobel Prize in Chemistry for contributions to the understanding of the electronic properties of materials Adolph Wilhelm Hermann Kolbe (1818–1884), German chemist known for Kolbe nitrile synthesis Izaak Kolthoff (1894–1993), Dutch-American chemist with abundant published research in diverse fields of analysis, the "Father of Analytical Chemistry" Arthur Kornberg (1918–2007), American biochemist, Nobel Prize in Chemistry (1959) for discovery of DNA polymerase Hans Kornberg (1928–2019), British biochemist known for research in microbial biochemistry Roger D. Kornberg (born 1947), 2006 Nobel Prize in Chemistry for elucidation of how genetic information from DNA is copied to RNA Teresa Kowalska (1946–2023), Polish chemist, specialized in the theory and application of chromatography Hans A.
Statins have a protective effect on blood vessels, and SSRIs such as fluoxetine may help symptoms, but the data is weak. PDE5 inhibitors, such as sildenafil and tadalafil, are used off-label to treat severe ischemia and ulcers in fingers and toes for people with secondary Raynaud's phenomenon; as of 2016, their role more generally in Raynaud's was not clear.
Sources: en.wikipedia.org
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.
Mass spectrometry gives the observed molecular mass, which is compared with the calculated value for the expected sequence. Reversed-phase chromatography shows retention behaviour and main peak purity. Peptide mapping adds sequence-level confirmation when the question requires it.
Typical entries include appearance, chromatographic purity as area percent, observed mass, water or residual solvent content, and the analytical methods used. The document reflects the lot tested and the laboratory that performed the work. It does not by itself establish that the delivered vial matches the tested lot.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.